But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...
Phase 1 data indicate Intellia’s medicine could be a powerful treatment for a cardiac form of ATTR amyloidosis. But rival drugs are further ahead.
EST Cathie Wood’s ARK Investment bought 176K shares of Crispr Therapeutics (CRSP) todayDon't Miss our Black Friday Offers:Discover the ...
Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...
Rather than training the algorithm on content scraped from the internet, scientists trained the AI on nearly three million ...
This study presents important findings on cold tolerance shared between hibernating and non-hibernating mammals, identifying a key molecule, GPX4, through multi-species genome-wide CRISPR screens. The ...
Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on CRSP: CRISPR Therapeutics NewsMORE Related Stocks Indices Commodities Currencies Stocks ...
Intellia's Phase 3 trial for NTLA-2002 shows promise, but limitations warrant caution. See why we believe NTLA stock is hold ...
Ken Hawkins, a retired teacher from Grants Pass, is first Oregon participant in phase 3 clinical trial Ken Hawkins, a 77-year ...
A virologist named Beata Halassy recently made headlines after publishing a report of successfully treating her own breast ...
Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...
Interesting Engineering on MSN16h
Meet Evo: Next-gen model predicts gene mutation effects with near-accuracyEvo marks the next frontier in machine learning by interpreting biological sequence data, including DNA, RNA, and proteins.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback